Scarica l'app Stockscreener
0.63
14.29%
-0.105
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ATXI Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.735
Aprire:
$0.748
Volume 24 ore:
916
Relative Volume:
1.68
Capitalizzazione di mercato:
$N/A
Reddito:
-
Utile/perdita netta:
$-10.38M
Rapporto P/E:
-0.1654
EPS:
-3.81
Flusso di cassa netto:
$-12.45M
1 W Prestazione:
-14.29%
1M Prestazione:
-14.29%
6M Prestazione:
-83.79%
1 anno Prestazione:
-96.88%
Intervallo 1D:
$0.748
$0.748
Intervallo di 1 settimana:
$0.748
$0.748
Portata 52W:
$0.5231
$0.748
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Nome
Avenue Therapeutics Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ATXI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
0.748 | 0 | 0 | -10.38M | -12.45M | -3.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.18 | 117.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
794.08 | 83.72B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
367.53 | 52.62B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
776.99 | 48.79B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
334.50 | 37.39B | 4.98B | 69.59M | 525.67M | 0.5197 |
Avenue Therapeutics Inc Borsa (ATXI) Ultime notizie
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Is PTC Therapeutics Inc. stock a defensive play in 20252025 Price Targets & Smart Investment Allocation Tips - ulpravda.ru
PTC Therapeutics (NASDAQ:PTCT) Upgraded to Buy at Wall Street Zen - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Upgraded at Wall Street Zen - MarketBeat
Avenue Therapeutics (ATXI) investors reelect six directors and ratify KPMG for 2025 - Stock Titan
Avenue Therapeutics shareholders elect directors, ratify KPMG auditor - TipRanks
Axsome Therapeutics shares gain 1.4% premarket after FDA grants priority review for co's Alzheimer's agitation drug - marketscreener.com
FDA supports Axsome’s NDA submission for narcolepsy drug AXS-12 By Investing.com - Investing.com Australia
ATXI: All directors were elected and KPMG LLP was ratified as auditor for 2025 - TradingView — Track All Markets
ATXI: All director nominees were elected and KPMG LLP was ratified as auditor for 2025 - TradingView — Track All Markets
Dyne Therapeutics (NASDAQ:DYN) Stock Rating Lowered by Wall Street Zen - MarketBeat
vTv Therapeutics (NASDAQ:VTVT) Upgraded at Wall Street Zen - MarketBeat
NexImmune (NASDAQ:NEXI) versus Avenue Therapeutics (NASDAQ:ATXI) Head-To-Head Comparison - Defense World
Avenue Therapeutics, Inc.Common Stock (NQ: ATXI - FinancialContent
Form 424B3 Ovid Therapeutics Inc. - StreetInsider
Will Neumora Therapeutics Inc. stock benefit from AI adoptionOil Prices & Weekly Setup with High ROI Potential - Улправда
Axsome Therapeutics stock hits all-time high at 152.98 USD - Investing.com
Axsome Therapeutics stock hits all-time high at 152.98 USD By Investing.com - Investing.com Australia
Axsome Therapeutics (AXSM) Receives a Buy from Wells Fargo - The Globe and Mail
Axsome Therapeutics (AXSM) Gets a Buy from Jefferies - The Globe and Mail
Avenue Therapeutics (ATXI) plans resale of 731,061 warrant-linked shares - Stock Titan
[RW] AVENUE THERAPEUTICS, INC. SEC Filing - Stock Titan
Spero Therapeutics (NASDAQ:SPRO) Upgraded to "Buy" at Wall Street Zen - MarketBeat
TG Therapeutics (NASDAQ:TGTX) Rating Increased to Buy at Wall Street Zen - MarketBeat
RBC Capital Sticks to Its Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail
Sionna Therapeutics (NASDAQ:SION) Upgraded at Wall Street Zen - MarketBeat
Axsome Confident On Regulatory, Commercial Outlook for Alzheimer's Agitation Drug Candidate, RBC Says - marketscreener.com
Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets - ts2.tech
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock - GlobeNewswire
Avenue Therapeutics Inc. (ATXI) Stock Price | Live Quotes & Charts | OTO - StocksToTrade
Spero Therapeutics (NASDAQ:SPRO) Stock Rating Lowered by Wall Street Zen - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Avenue Therapeutics (NASDAQ: ATXI) 2025 proxy on director elections, KPMG audit and Fortress control - Stock Titan
Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet - WV News
Axsome therapeutics CEO Tabuteau sells $11.6 million in shares By Investing.com - Investing.com India
Axsome therapeutics CEO Tabuteau sells $11.6 million in shares - Investing.com
Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade - WV News
Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Wall Street Zen to "Buy" - MarketBeat
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice - USA Today
Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug - Stocktwits
Avenue Therapeutics Leads Six-Month Stock Performance with 267.29% Return - Markets Mojo
Axsome Therapeutics stock reaches all-time high of 152.94 USD By Investing.com - Investing.com Australia
Axsome Therapeutics stock reaches all-time high of 152.94 USD - Investing.com
Avenue Therapeutics Leads Six-Month Stock Performance with 253.98% Return - Markets Mojo
Avenue Therapeutics Leads Six-Month Stock Performance with 257.7% Return - Markets Mojo
Village Farms International Leads with 276.7% Return in Recent Six Months - Markets Mojo
Axsome Therapeutics to Participate in Upcoming Investor Conferences - marketscreener.com
Avenue Therapeutics Announces 2025 Annual Meeting Date - The Globe and Mail
[8-K] AVENUE THERAPEUTICS, INC. Reports Material Event | ATXI SEC FilingForm 8-K - Stock Titan
Village Farms International Leads with 282% Return in Recent Performance Surge - Markets Mojo
Avenue Therapeutics Inc Azioni (ATXI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
0.37%
Capitalizzazione:
|
Volume (24 ore):